Total Payments
$2.1M
2024 Payments
$164,736
Companies
51
Transactions
1,881
Medicare Patients
1,531
Medicare Billing
$334,770
Payment Breakdown by Category
Other$1.7M (79.3%)
Travel$273,926 (12.9%)
Consulting$114,583 (5.4%)
Food & Beverage$43,142 (2.0%)
Research$6,650 (0.3%)
Education$358.12 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.6M | 556 | 74.4% |
| Travel and Lodging | $273,926 | 683 | 12.9% |
| Consulting Fee | $114,583 | 51 | 5.4% |
| Honoraria | $99,391 | 38 | 4.7% |
| Food and Beverage | $43,142 | 540 | 2.0% |
| Unspecified | $6,650 | 5 | 0.3% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $3,870 | 2 | 0.2% |
| Education | $358.12 | 6 | 0.0% |
Payments by Type
General
$2.1M
1,876 transactions
Research
$6,650
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $254,659 | 239 | $0 (2024) |
| Janssen Biotech, Inc. | $246,485 | 244 | $0 (2024) |
| Celgene Corporation | $203,744 | 153 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $202,403 | 129 | $0 (2024) |
| Genentech USA, Inc. | $159,692 | 115 | $0 (2023) |
| Pharmacyclics LLC, An AbbVie Company | $111,329 | 171 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $107,191 | 86 | $0 (2024) |
| Astellas Pharma US Inc | $96,744 | 81 | $0 (2024) |
| ABBVIE INC. | $93,971 | 87 | $0 (2024) |
| Karyopharm Therapeutics Inc. | $84,452 | 49 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $164,736 | 181 | PFIZER INC. ($34,774) |
| 2023 | $254,531 | 200 | E.R. Squibb & Sons, L.L.C. ($64,215) |
| 2022 | $288,387 | 230 | E.R. Squibb & Sons, L.L.C. ($108,833) |
| 2021 | $172,029 | 131 | Janssen Biotech, Inc. ($31,786) |
| 2020 | $191,585 | 125 | Celgene Corporation ($46,574) |
| 2019 | $386,385 | 367 | Amgen Inc. ($73,356) |
| 2018 | $319,025 | 319 | Amgen Inc. ($72,125) |
| 2017 | $343,614 | 328 | Celgene Corporation ($55,181) |
All Payment Transactions
1,881 individual payment records from CMS Open Payments — Page 1 of 76
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $825.00 | General |
| Category: Oncology | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,176.00 | General |
| Category: Hematology | ||||||
| 12/10/2024 | Incyte Corporation | MONJUVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,055.00 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Incyte Corporation | MONJUVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,370.00 | General |
| Category: Oncology | ||||||
| 12/02/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,625.00 | General |
| Category: Oncology | ||||||
| 11/25/2024 | PFIZER INC. | ELREXFIO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,275.00 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,625.00 | General |
| Category: Oncology | ||||||
| 11/20/2024 | PFIZER INC. | ELREXFIO (Drug) | Food and Beverage | In-kind items and services | $120.14 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $25.01 | General |
| 11/13/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $125.05 | General |
| Category: Hematology | ||||||
| 10/15/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $831.00 | General |
| Category: Oncology | ||||||
| 10/10/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $26.65 | General |
| Category: Oncology | ||||||
| 10/01/2024 | PFIZER INC. | ELREXFIO (Drug) | Travel and Lodging | In-kind items and services | $176.31 | General |
| Category: ONCOLOGY | ||||||
| 10/01/2024 | PFIZER INC. | ELREXFIO (Drug) | Travel and Lodging | In-kind items and services | $156.63 | General |
| Category: ONCOLOGY | ||||||
| 09/27/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,575.00 | General |
| Category: Oncology | ||||||
| 09/25/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | In-kind items and services | $700.88 | General |
| Category: Oncology | ||||||
| 09/25/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | In-kind items and services | $160.03 | General |
| Category: Oncology | ||||||
| 09/24/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 09/24/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | In-kind items and services | $5.50 | General |
| Category: Oncology | ||||||
| 09/21/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $29.94 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 09/19/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: Oncology | ||||||
| 09/14/2024 | PFIZER INC. | ELREXFIO (Drug) | Travel and Lodging | In-kind items and services | $569.76 | General |
| Category: ONCOLOGY | ||||||
| 09/13/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | In-kind items and services | $5.50 | General |
| Category: Oncology | ||||||
| 09/12/2024 | PFIZER INC. | ELREXFIO (Drug) | Travel and Lodging | In-kind items and services | $155.23 | General |
| Category: ONCOLOGY | ||||||
| 09/11/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,550.00 | General |
| Category: Infectious Diseases | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AML CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $6,650 | 5 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 457 | 1,064 | $319,920 | $104,660 |
| 2022 | 5 | 289 | 559 | $139,165 | $42,547 |
| 2021 | 6 | 380 | 1,362 | $284,250 | $105,120 |
| 2020 | 7 | 405 | 1,283 | $226,020 | $82,443 |
Total Patients
1,531
Total Services
4,268
Medicare Billing
$334,770
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 179 | 508 | $182,880 | $58,740 | 32.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 180 | 342 | $84,075 | $27,326 | 32.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 24 | 61 | $18,540 | $6,773 | 36.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 24 | 76 | $15,510 | $5,613 | 36.2% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 21 | 47 | $6,165 | $2,168 | 35.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 14 | 14 | $6,270 | $2,085 | 33.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 15 | 16 | $6,480 | $1,956 | 30.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 161 | 266 | $65,170 | $17,245 | 26.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 75 | 139 | $50,040 | $16,645 | 33.3% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 22 | 90 | $9,000 | $3,360 | 37.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 14 | 33 | $8,910 | $3,206 | 36.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 17 | 31 | $6,045 | $2,091 | 34.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 245 | 1,045 | $228,240 | $84,478 | 37.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 27 | 66 | $17,400 | $6,417 | 36.9% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 43 | 167 | $16,700 | $6,005 | 36.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 33 | 51 | $9,510 | $3,456 | 36.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 13 | 13 | $7,200 | $2,803 | 38.9% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 19 | 20 | $5,200 | $1,961 | 37.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 240 | 952 | $176,720 | $63,513 | 35.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 37 | 88 | $15,630 | $6,004 | 38.4% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 35 | 113 | $10,760 | $4,235 | 39.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 23 | 42 | $10,610 | $4,075 | 38.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 16 | 16 | $8,220 | $3,206 | 39.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 12 | 12 | $3,180 | $1,241 | 39.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 42 | 60 | $900.00 | $168.36 | 18.7% |
About Dr. Michael Schuster, MD
Dr. Michael Schuster, MD is a Internal Medicine healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1669569752.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Schuster, MD has received a total of $2.1M in payments from pharmaceutical and medical device companies, with $164,736 received in 2024. These payments were reported across 1,881 transactions from 51 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.6M).
As a Medicare-enrolled provider, Schuster has provided services to 1,531 Medicare beneficiaries, totaling 4,268 services with total Medicare billing of $334,770. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location New York, NY
- Active Since 10/09/2006
- Last Updated 06/27/2013
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1669569752
Products in Payments
- DARZALEX (Biological) $159,357
- IMBRUVICA (Drug) $133,129
- Revlimid (Drug) $112,981
- Imbruvica (Drug) $92,399
- REBLOZYL (Biological) $91,502
- XPOVIO (Drug) $84,452
- Pomalyst (Drug) $82,387
- Blincyto (Biological) $82,179
- NINLARO (Drug) $80,884
- VENCLEXTA (Biological) $77,585
- BRUKINSA (Drug) $70,365
- Zydelig (Drug) $69,507
- Neulasta (Biological) $67,604
- MONJUVI (Drug) $66,820
- Venclexta (Drug) $49,804
- Cresemba (Drug) $45,581
- SARCLISA (Biological) $45,015
- Kyprolis (Biological) $43,561
- VENCLEXTA (Drug) $42,066
- ONUREG (Drug) $38,699
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in New York
Dr. Stephen Saletan, M.d, M.D
Internal Medicine — Payments: $2.7M
Internal Medicine $2.7M
Dr. Ziad Ali, Md Dphil, MD DPHIL
Internal Medicine — Payments: $1.7M
Internal Medicine $1.7M
Dr. James Underberg, Md, MD
Internal Medicine — Payments: $1.5M
Internal Medicine $1.5M
Dr. Ricky Hsu, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Gail Roboz, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M
Gary Slatko, Md, MD
Internal Medicine — Payments: $910,320
Internal Medicine $910,320